Adaptimmune Therapeutics (ADAP) to Release Earnings on Monday

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) will announce its earnings results before the market opens on Monday, May 9th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) last issued its earnings results on Monday, March 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.03). Adaptimmune Therapeutics had a negative return on equity of 61.15% and a negative net margin of 2,571.00%. The company had revenue of $1.42 million during the quarter, compared to the consensus estimate of $80.25 million. During the same quarter in the prior year, the company earned ($0.24) earnings per share. On average, analysts expect Adaptimmune Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptimmune Therapeutics stock opened at $1.76 on Monday. The company has a 50 day moving average price of $2.08 and a 200-day moving average price of $3.27. Adaptimmune Therapeutics has a fifty-two week low of $1.65 and a fifty-two week high of $6.86.

A number of equities research analysts have weighed in on ADAP shares. StockNews.com assumed coverage on Adaptimmune Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating for the company. SVB Leerink cut their price objective on shares of Adaptimmune Therapeutics from $7.00 to $3.00 and set a “market perform” rating on the stock in a report on Tuesday, March 15th. Finally, Zacks Investment Research lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Adaptimmune Therapeutics presently has an average rating of “Hold” and an average price target of $6.92.

A number of institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of Adaptimmune Therapeutics by 34.3% during the second quarter. Wells Fargo & Company MN now owns 15,670 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 3,999 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth about $1,604,000. State Street Corp grew its stake in Adaptimmune Therapeutics by 8.4% during the 4th quarter. State Street Corp now owns 614,993 shares of the biotechnology company’s stock valued at $2,306,000 after purchasing an additional 47,784 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Adaptimmune Therapeutics by 33.0% in the fourth quarter. Squarepoint Ops LLC now owns 42,389 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 10,508 shares during the period. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Adaptimmune Therapeutics by 38.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 80,521 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 22,568 shares during the last quarter.

About Adaptimmune Therapeutics (Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

See Also

Earnings History for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.